• Purple Biotech Reports Additional Positive Interim Data from its Randomized Phase 2 Study with its Lead Oncology Therapeutic Candidate CM24 | Morningstar

    Source: Buzz FX / 18 Sep 2024 07:51:13   America/New_York

    N/A
Share on,